Ryvu Therapeutics (LTS:0RKT) Ending Cash Position: zł49.70 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKT Ryvu Therapeutics SA LTS:0RKT
65 GF Score
Price zł30.25
GF Value zł82.59
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Ending Cash Position?

Ryvu Therapeutics LTS:0RKT 65 Ending Cash Position is zł49.70 Mil as of Mar. 2026. GuruFocus rates LTS:0RKT with a GF Score™ of 65/100 and a GF Value™ of zł82.59. The stock has 3 warning signs investors should review.

Ryvu Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was zł49.70 Mil.

Ryvu Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 (zł89.12 Mil) to Dec. 2025 (zł59.61 Mil) and declined from Dec. 2025 (zł59.61 Mil) to Mar. 2026 (zł49.70 Mil).

Ryvu Therapeutics's annual Ending Cash Position increased from Dec. 2023 (zł57.94 Mil) to Dec. 2024 (zł160.07 Mil) but then declined from Dec. 2024 (zł160.07 Mil) to Dec. 2025 (zł59.61 Mil).

Ryvu Therapeutics Ending Cash Position Related Terms

Ryvu Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics Ending Cash Position Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.24 101.92 57.94 160.07 59.61

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 151.76 107.17 89.12 59.61 49.70
LTS:0RKT
65GF Score
Ryvu Therapeutics SA LTS:0RKT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryvu Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Ryvu Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=160.073+-100.467
=59.61

Ryvu Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=59.606+-9.91
=49.70

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of zł49.70 Mil mean?
Ryvu Therapeutics (LTS:0RKT) has a Ending Cash Position of zł49.70 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ryvu Therapeutics and its competitors.
Is Ryvu Therapeutics' Ending Cash Position too high?
Ryvu Therapeutics' current Ending Cash Position is zł49.70 Mil. Overall, Ryvu Therapeutics has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Ending Cash Position compare to VRTX and REGN?
Ryvu Therapeutics' Ending Cash Position of zł49.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ryvu Therapeutics and its competitors. Ryvu Therapeutics's current Ending Cash Position is zł49.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current Ending Cash Position of zł49.70 Mil. The stock's GF Value™ is zł82.59, compared to a current price of zł30.25 — trading 63.4% below its estimated fair value. The current Ending Cash Position is zł49.70 Mil. Ryvu Therapeutics' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current Ending Cash Position is zł49.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł30.25 is trading 63.4% below its estimated GF Value™ of zł82.59.

Key valuation signals for LTS:0RKT:

  • Ending Cash Position: zł49.70 Mil
  • GF Value™: zł82.59 vs. price of zł30.25 (63.4% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
65GF Score

Get the complete analysis for LTS:0RKT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł30.25
Price
zł82.59
GF Value